Jasbir Seehra insider trades

Open-market stock purchases and sales by Jasbir Seehra, CHIEF EXECUTIVE OFFICER at Keros Therapeutics, Inc, from SEC Form 4 filings since Jun 15, 2018.

Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -31%.

Recent trades

DateStockTradeValue
Apr 2, 2026KROS Keros Therapeutics, IncBought (not open market)—
Feb 24, 2026KROS Keros Therapeutics, IncBought (not open market)—
Feb 24, 2026KROS Keros Therapeutics, IncBought (not open market)—
Feb 19, 2026KROS Keros Therapeutics, IncSold$113K
Jan 7, 2026KROS Keros Therapeutics, IncBought (not open market)—

Companies traded

  • KROS Keros Therapeutics, Inc: 1 buy, 1 sale, last Apr 2, 2026
  • ELOX Eloxx Pharmaceuticals, Inc: other filings, last Jun 15, 2022

Get free alerts when Jasbir Seehra files a new trade →